Tech Company Financing Transactions
Perceive Biotherapeutics Funding Round
On 1/6/2023, Perceive Biotherapeutics received $78 million in Series B funding from Johnson & Johnson Innovation, Braidwell and Catalio Capital Management.
Transaction Overview
Company Name
Announced On
1/6/2023
Transaction Type
Venture Equity
Amount
$78,000,000
Round
Series B
Investors
Proceeds Purpose
The company intends to use the funds to accelerate its progress as it drives lead AMD program into the clinic and continues development progress across extensive ophthalmology pipeline.
Company Information
Company Status
Private & Independent
Industry
Biopharmaceutical
Mailing Address
6000 Shoreline Drive, Suite 206
South San Francisco, CA 94080
USA
South San Francisco, CA 94080
USA
Phone
Undisclosed
Website
Email Address
Overview
Exclusivity to decades of academic research elucidating two of the strongest protective biologies in retinal degeneration. Novel therapeutics to prevent the largest causes of irreversible blindness preparing for clinic with lead programs in dry AMD & neuroprotection. Team with exceptional insight & highly successful track record translating science through clinical development into strategic value.
Profile
Social Media
Company News
Facebook
YouTube
Management Team
Title
Name
Email & Social
Chief Executive Officer
K. Angela Macfarlane
Browse more venture capital transactions:
Prev: 1/6/2023: Doorstead venture capital transaction
Next: 1/6/2023: KeyCare venture capital transaction
Share this article
About Our Venture Capital Transactions Database
Our team works diligently to record tech company VC transactions. All VC database entries reported here are sourced from a variety of public sources. The information comes to us via our partnership with VentureDeal.com, an affiliated venture.
Additional Resources for Entrepreneurs